BICNU 100 MG — DIN 00297763
CARMUSTINE : 100 MG · MARCAN PHARMACEUTICALS INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BICNU?
BICNU 100 MG contains CARMUSTINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 00297763, held by MARCAN PHARMACEUTICALS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BICNU used for?
BiCNU (carmustine) is indicated as palliative therapy to surgery and radiotherapy as a single agent or in established combination therapy with other chemotherapeutic agents in the following: Brain tumours - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumours; Multiple myeloma - in combination with glucocorticoid such as prednisone; Hodgkin's disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy; Non-Hodgkin's lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy; Tumours of the Gastrointestinal tract; Malignant melanoma when used in combination with other antineoplastic drugs.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Carmustine cost around the world?
Carmustine is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
14 pack listings across 13 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Carmustine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Carmustine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Carmustine, across 4 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MARCAN PHARMACEUTICALS INC | 2 | 1 | BICNU | Sourceable in Canada |
| STERIMAX INC | 1 | 1 | CARMUSTINE FOR INJECTION USP | Sourceable in Canada |
| EISAI LIMITED | 1 | 0 | GLIADEL WAFER | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 1 mL fill in 5 mL amber glass vial and is available in pack size of 1 vial. Carmustine for Inj ection 300 mg/3mL solution for infusion is a clear, pale yellow to yellow color solution. It is available as 3 mL fill in 5 mL amber glass vial with 20 mm lyo rubber stopper and 20 mm purple MT flip off seal and is available in pack size of 1 vial. |
| Storage | After reconstitution as recommended, the reconstituted solution is stable for 480 hours under refrigeration (2°C - 8°C) and 24 hours at temperature (25°C ±2°C) in glass container. Examine reconstituted vials for crystal formation prior to use. The reconstituted diluted solution should be used within 8 hours at 25 °C ± 2 °C and protected from light. The reconstituted diluted solution can be stored in the refrigerator (2 - 8° C) for 48 hours and, protected from light, for an additional 6 hours at temperature ( 25°C ± 2°C ) . |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Carmustine |
|---|---|
| ATC code | L01AD01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00297763 |
|---|---|
| DIN (unpadded, as printed on some documents) | 297763 |
| Brand name | BICNU |
| Generic / active ingredient | CARMUSTINE : 100 MG |
| Market authorization holder | MARCAN PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | L01AD01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01AD |
| Current status | MARKETED |
| Status date | 19-Sep-2017 |
| Original market date | 1970-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARMUSTINE FOR INJECTION USP | 100 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02531879 |
| BICNU | 100 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | CANCELLED POST MARKET | 02555093 |
| GLIADEL WAFER | 7.7 MG | WAFER | EISAI LIMITED | CANCELLED POST MARKET | 02238985 |
2 · Same class — other molecules in ATC L01AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Carmustine | BICNU · CARMUSTINE FOR INJECTION USP · GLIADEL WAFER | 4 | 2 | Yes |
| Lomustine | CEENU | 3 | 2 | Yes |
| Streptozocin | ZANOSAR STERILE POWDER | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01AA | Bendamustine · Chlorambucil · Chlormethine · Cyclophosphamide · Ifosfamide · +1 more | 64 | 31 |
| L01AX | Dacarbazine · Temozolomide | 42 | 26 |
| L01AC | Thiotepa | 9 | 6 |
| L01AB | Busulfan · Treosulfan | 10 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BICNU called?
The same molecule, Carmustine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Carmustine | Latin | Iceland |
| Carmustine for Injection, USP | Latin | Saudi Arabia |
| Gliadel | Latin | Australia |
| Gliadel Wafer | Latin | South Africa |
| Stenar | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.